New Launch13 Jan 2025, 02:30 pm
Wockhardt's Zaynich Achieves Over 97% Efficacy in Clinical Study for Serious Infections
AI Summary
In a ground-breaking clinical study, Wockhardt's Zaynich (Zidebactam/Cefepime, WCK 5222) demonstrated over 97% clinical efficacy in treating seriously ill patients with infections caused by carbapenem-resistant (including meropenem-resistant) Gram-negative pathogens. The study involved a range of severe infections and diverse XDR Gram-negatives such as Acinetobacter spp., Pseudomonas spp., Klebsiella spp., and E. coli. Zaynich showed high pathogen eradication rates and saved more than 100 critically ill patients' lives. The study was conducted across 15 top-rated tertiary care hospitals nationwide and is significant due to the global threat posed by antimicrobial resistance.
Key Highlights
- Zaynich achieves over 97% clinical efficacy in treating serious infections caused by carbapenem-resistant Gram-negative pathogens
- The study involved a range of severe infections and diverse XDR Gram-negatives
- Zaynich showed high pathogen eradication rates and saved more than 100 critically ill patients' lives
- The study was conducted across 15 top-rated tertiary care hospitals nationwide
- Zaynich targets all Gram-negative pathogens identified as critical priorities by the U.S. CDC and the WHO